|
Pronunciation |
|
(proe
TYE re
lin) |
|
|
U.S. Brand
Names |
|
Relefact® TRH Injection;
Thypinone®
Injection |
|
|
Generic
Available |
|
No |
|
|
Synonyms |
|
Lopremone; Thyrotropin Releasing Hormone; TRH |
|
|
Pharmacological Index |
|
Diagnostic Agent, Thyroid Function |
|
|
Use |
|
Adjunct in the diagnostic assessment of thyroid function, and an adjunct to
other diagnostic procedures in patients with pituitary or hypothalamic
dysfunction; also causes release of prolactin from the pituitary and is used to
detect defective control of prolactin secretion |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Hypersensitivity to protirelin additives |
|
|
Adverse
Reactions |
|
>10%:
Central nervous system: Headache, lightheadedness
Dermatologic: Flushing of face
Gastrointestinal: Nausea, xerostomia
Genitourinary: Urge to urinate
1% to 10%:
Central nervous system: Anxiety
Endocrine & metabolic: Breast enlargement and leaking in lactating women
Gastrointestinal: Bad taste in mouth, abdominal discomfort
Neuromuscular & skeletal: Tingling
Miscellaneous: Diaphoresis |
|
|
Drug
Interactions |
|
Decreased effect: Aspirin, levodopa, thyroid hormones, adrenocorticoid
drugs |
|
|
Mechanism of
Action |
|
Increase release of thyroid stimulating hormone from the anterior
pituitary |
|
|
Pharmacodynamics/Kinetics |
|
Peak TSH levels: 20-30 minutes
Duration: TSH returns to baseline after ~3 hours
Serum half-life, mean plasma: 5 minutes |
|
|
Usual Dosage |
|
I.V.:
Children 6-16 years: 7 mcg/kg to a maximum dose of 500 mcg
Adults: 500 mcg (range 200-500 mcg) |
|
|
Administration |
|
Administer I.V. bolus over 15-30 seconds with patient remaining in supine
position; monitor blood pressure frequently during and 15 minutes after
administration |
|
|
Mental Health: Effects
on Mental Status |
|
Dizziness is common; may cause anxiety |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
None reported |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
>10% of patients experience dry mouth |
|
|
Nursing
Implications |
|
Keep patient supine during drug administration; administer undiluted direct
I.V. over 15-30 seconds with the patient remaining supine for an additional 15
minutes
Monitor blood pressure, prolactin, TSH, T4 and
T3 |
|
|
Dosage Forms |
|
Injection: 500 mcg/mL (1 mL) |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|